Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma

Veterinary and Comparative Oncology

Volumn 5, Issue 4, 2007, Pages 219-231

  Turek, M M ^a   Thamm, D H ^a   Mitzey, A ^a   Kurzman, I D ^a,b   Huelsmeyer, M K ^a   Dubielzig, R R ^a   Vail, D M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Chemotherapy; Dog; Granulocyte monocyte colony stimulating factor; Idiotype; Immunotherapy; Tumour cell vaccine

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 66149160730     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2007.00128.x     Document Type: Article

References (63)

1. Vail DM, MacEwen EG and Young K. Canine lymphoma and lymphoid leukemias. In: Small Animal Clinical Oncology, 3rd edn., SJ Withrow and EG MacEwen, eds., Philadelphia, WB Saunders Co, 2001: 558-590.
2. Garrett LD, Thamm DH, Chun R, Dudley R and Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002; 16: 704-709.
3. Vail DM and Thamm DH. Spontaneously occurring tumors in companion animals as models for drug development. In: Anticancer Drug Development Guide, 2nd edn., BA Teicher, ed., Totowa, NJ, Humana Press Inc., 2004: 259-286.
4. MacDonald VS, Thamm DH, Kurzman ID, Turek MM and Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? Journal of Veterinary Internal Medicine 2005; 19: 732-736.
5. Timmerman JM. Immunotherapy for lymphomas. International Journal of Hematology 2003; 77: 444-455.
6. Montross S and Timmerman JM. Vaccine therapies for non-Hodgkin's lymphomas. Cancer Treatment and Research 2006; 131: 283-315.
7. Vose JM. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: A promising approach. Hematological Oncology 2006; 24: 47-55.
8. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG and Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine 1996; 2: 52-58.
9. Bendandi M, Gocke CD, Kobrin CB, Beuko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL and Kwak LW. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma. Nature Medicine 1999; 5: 1171-1177.
10. Baskar S, Kobrin CB and Kwak LW. Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. Journal of Clinical Investigation 2004; 113: 1498-1510.
11. Yi Q. Vaccines for hematological malignancies. In: Handbook of Cancer Vaccines, MA Morse, TM Clay and HK Lyerly, eds., Totowa, NJ, Humana Press, 2004: 425-449.
12. Jeglum KA, Young KM, Barnsley K, Whereat A, McGrath D and Hatson C. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma. Journal of Biological Response Modifiers 1986; 5: 168-175.
13. Jeglum KA, Young KM, Barnsley K and Whereat A. Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer 1988; 61: 2042-2050.
14. Kobrin CB and Kwak LW. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Investigation 1997; 15: 577-587.
15. Kwak LW, Thielemans K and Massaia M. Idiotypic vaccination as therapy for multiple myeloma. Seminars in Hematology 1999; 36: 34-37.
16. Kaminski MS, Kitamura K, Maloney DG and Levy R. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. Journal of Immunology 1987; 138: 1289-1296.
17. George AJ, Folkard SG, Hamblin TJ and Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. Journal of Immunology 1988; 141: 2168-2174.
18. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R and Levy R. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Annals of the New York Academy of Sciences 1993; 690: 385-387.
19. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B and Levy R. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997; 89: 3129-3135.
20. Campbell JF, Esserman L, Byars NE, Allison AC and Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. Journal of Immunology 1990; 145: 1029-1036.
21. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C and Krensky AM. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996; 88: 580-589.
22. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA and Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. New England Journal of Medicine 1992; 327: 1209-1215.
23. Kwak LW, Young HA, Pennington RW and Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 10972-10977.
24. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL and Kwak LW. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine 1999; 5: 1171-1177.
25. Barrios Y, Cabrera R, Yanez R, Briz M, Plaza A, Fores R, Fernandez MN and Diaz-Espada F. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Hematologica 2002; 87: 400-407.
26. Borrello IM and Sotomayer EM. Cancer vaccines for hematologic malignancies. Cancer Control 2002; 9: 138-151.
27. Briones J, Timmerman JM, Panicalli DL and Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. Journal of the National Cancer Institute 2003; 95: 548-555.
28. Radford KJ, Vari F and Hart DNJ. Vaccine strategies to treat lymphoproliferative disorders. Pathology 2005; 37: 534-550.
29. Clay TM, Mosca PJ, Lyerly K and Morse MA. Whole-cell vaccines. In: Handbook of Cancer Vaccines, MA Morse, TM Clay and HK Lyerly, eds., Totowa, NJ, Humana Press Inc., 2004: 249-252.
30. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS and MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Human Gene Therapy 1998; 9: 1851-1861.
31. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Yang NS and MacEwen EG. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Therapy 1999; 6: 26-36.
32. Jeglum KA. Melanomas. In: Current Therapy in Equine Medicine, 4th edn., NE Robinson, ed., Philadelphia, WB Saunders Co, 1997: 399-400.
33. Gollagher RD, Ziola B and Chelack BJ. Immunotherapy of cutaneous lymphosarcoma using low dose cyclophosphamide and autologous tumor cells infected with vaccinia virus. Canadian Veterinary Journal 1993; 3: 371-373.
34. Jeglum KA, Young KM, Barnsley K and Whereat A. Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma. Cancer 1988; 61: 2042-2050.
35. Alexander AN, Huelsmeyer MK, Mitzey AM, Dubielzig RR, Kurzman ID, MacEwen EG and Vail DM. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunology and Immunotherapy 2006; 55: 433-442.
36. Tao MH and Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755-757.
37. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D and Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 3539-3543.
38. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K and Gilboa E. Retroviral vector mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Research 1990; 50: 7820-7825.
39. Qin H and Chatterjee SK. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Human Gene Therapy 1996; 7: 1853-1860.
40. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K and Jamada H. Antitumor effect induced by GM-CSF gene-modified tumor vaccination: comparison of adenovirus and retrovirus-mediated genetic transmission. Journal of Cancer Research and Clinical Oncology 1995; 121: 587-592.
41. Wakimoto H, Abe J and Tsumoda R. Intensified antitumor immunity by a cancer vaccine that produces granulocyte macrophage colony stimulating factor plus interleukin 4. Cancer Research 1996; 56: 1828-1833.
42. Chen TT, Tao MH and Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. Journal of Immunology 1994; 153: 4775-4787.
43. Gasson JC. Molecular physiology of granulocyte-macrophage colony stimulating factor. Blood 1991; 77: 1131-1145.
44. Morrisey PJ, Bressler L, Park LS, Alpert A and Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. Journal of Immunology 1987; 139: 1113-1119.
45. Smith PD, Lamerson CL, Wong HL, Wahl LM and Wahl SM. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. Journal of Immunology 1990; 144: 3829-3834.
46. Fischer HG, Frosch S, Reske K and Reske-Kunz AB. Granulocyte-macrophage colony-stimulating factor activated macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. Journal of Immunology 1988; 141: 3882-3888.
47. Heufler C, Koch F and Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediated the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. Journal of Experimental Medicine 1988; 167: 700-705.
48. Cella M, Engering A, Pinet V, Pieters J and Lansavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 1997; 388: 782-787.
49. Strehl J, Selmayr M, Kremer J.-P, Hultner L, Lindhofer H and Mocikat R. Gene therapy of B-cell lymphoma with cytokine gene-modified trioma cells. International Journal of Cancer 1999; 83: 113-120.
50. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD and Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. Journal of Immunology 1999; 163: 1552-1561.
51. Nomura T, Yasuda K, Yamada T, Okamoto S, Mahato RI, Watanabe Y, Takakura Y and Hashida M. Gene expression and antitumor effects following direct interferon (IFN) gamma gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Therapy 1998; 6: 121-129.
52. Pisetsky DS and Reich CF III. The influence of lipofectin on the in vitro stimulation of murine spleen cells by bacterial DNA and plasmid DNA vectors. Journal of Interferon and Cytokine Research 1999; 19: 1219-1226.
53. Mueller RS, Veir J, Fieseler KV and Dow SW. Use of immunostimulatory liposome nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis-a pilot study. Veterinary Dermatology 2005; 16: 61-68.
54. Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ and Helfand SC. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Veterinary Immunology and Immunopathology 1999; 70: 189-201.
55. Gilboa E. The promise of cancer vaccines. Nature Reviews Cancer 2004; 4: 401-411.
56. Blobe GC. Escape of tumors from the immune system. In: Handbook of Cancer Vaccines, MA Morse, TM Clay and HK Lyerly, eds., Totowa, NJ, Humana Press, 2004: 85-98.
57. Machiels J-PH, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Research 2001; 61: 3689-3697.
58. Emens LA, Machiels JP, Reilly RT and Jaffee EM. Chemotherapy: Friend or foe to cancer vaccines? Current Opinion in Molecular Therapeutics 2001; 3: 77-84.
59. Nigam A, Yacavone RF, Zahurak ML, Johns CM, Pardoll DM, Piantadosi S, Levitsky HI and Nelson WG. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. International Journal of Oncology 1998; 12: 161-170.
60. Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffe E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K and Wolff A. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Human Gene Therapy 2004; 15: 313-337.
61. Walter CU, Biller BJ, Lana SE, Bachand AM and Dow SW. Effects of chemotherapy on immune responses in dogs with cancer. Journal of Veterinary Internal Medicine 2006; 20: 342-347.
62. Clay TM, Morse MA, Mosca PJ, Hobeika A, Niedzwiecki D and Lyerly HK. Analysis of cellular immune responses in cancer vaccine trials. In: Handbook of Cancer Vaccines, MA Morse, TM Clay and HK Lyerly, eds., Totowa, NJ, Humana Press,. 2004: 527-542.
63. Somasundaram R, Zhang T and Herlyn D. Analysis of humoral immune responses in vaccine trials. In: Handbook of Cancer Vaccines, MA Morse, TM Clay and HK Lyerly, eds., Totowa, NJ, Humana Press, 2004: 543-561.